Joint venture potential Acurian positions itself as a transformation under Accelerated Enrollment Solutions (AES), indicating a strategic partner model that combines site and enrollment capabilities. Sales opportunities could target sponsors seeking integrated enrollment and site management solutions for faster trial timelines and improved budget certainty.

NAFLD/NASH focus Recent launches target enrolling patients for NAFLD and NASH, suggesting a specialization in hepatology trials. Business development should explore sponsors with NAFLD/NASH portfolios or evolving hepatic endpoints, leveraging Acurian/AES capabilities for optimized patient recruitment.

Crohn’s and UC app The COLO app launch for Crohn’s disease and ulcerative colitis indicates a patient-reported outcomes and symptom-tracking angle. Opportunities exist to sell patient-centric enrollment solutions, digital engagement tools, and remote monitoring capabilities to sponsors running GI trials.

Strategic leadership shifts Leadership movements and executive transitions, including the departure of an executive director in 2019 and new leadership in business development, signal potential openness to new partnerships and strategic collaborations. Leverage these moments to propose refreshed pricing, pilot programs, or co-development opportunities.

Scale and ecosystem As part of a broader ecosystem through AES and Synexus collaborations, Acurian positions access to a global site network and enrollment expertise. Target large sponsors seeking global patient recruitment, site-network reliability, and end-to-end trial acceleration with proven time-to-market benefits.